Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07366112 | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment(DNACDKHR) | recruiting | Phase 2 | 158 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05534438 | A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | recruiting | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 |
| Jul 10, 2026 |
| clinicaltrials |
| NCT07570524 | Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer(PRIME-TNBC) | recruiting | — | 200 | Center Eugene MarquisOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05941520 | Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer | recruiting | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07011654 | Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05376878 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | recruiting | Phase 4 | 10 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05677802 | Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer | recruiting | N/A | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673029 | A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | recruiting | Phase 3 | 228 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05770531 | Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy | recruiting | Phase 2 | 160 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664579 | Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | recruiting | — | 160 | City of Hope Medical CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04891068 | BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer(BRE-04) | recruiting | Phase 2 | 40 | University of Illinois at ChicagoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07046923 | A Study of LY4175408 in Participants With Advanced Cancer | recruiting | Phase 1 | 240 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT07158021 | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial | recruiting | Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | recruiting | Phase 1 | 396 | ExelixisINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06892093 | Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients | recruiting | N/A | 308 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT04517838 | Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | recruiting | — | 230 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06028022 | Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05704283 | 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer | recruiting | Early Phase 1 | 55 | Mayo ClinicOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07474090 | Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial(STEPS-BC) | recruiting | N/A | 120 | Wake Forest University Health SciencesOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647263 | Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00991094 | Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05178498 | Impact of Dietary Inflammatory Potential on Breast Cancer Risk | recruiting | — | 960 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06763328 | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | recruiting | Phase 3 | 80 | City of Hope Medical CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03936478 | Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer(MAPBI) | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06224673 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | recruiting | Phase 2 | 36 | Laura Huppert, MD, BAOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07339306 | A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts | recruiting | N/A | 300 | The Fourth Affiliated Hospital of China Medical UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06771609 | Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07198724 | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer(ERADICATE) | recruiting | Phase 1 / Phase 2 | 65 | Kristina A. FanucciOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07307664 | Increasing Germline Genetic Testing for Patients With Cancer(gLHS) | recruiting | N/A | 1,000 | Josh PetersonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635342 | Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 182 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04529044 | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | recruiting | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06297265 | Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery | recruiting | N/A | 50 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04638725 | Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer(SIGHER) | recruiting | — | 9,000 | Centre Paul StraussOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05660083 | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | recruiting | Phase 2 | 36 | The Methodist Hospital Research InstituteOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05741164 | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer | recruiting | Phase 2 | 37 | Emory UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07483307 | A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | recruiting | Phase 2 | 176 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 596 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07616440 | Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer | recruiting | N/A | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2026source: clinicaltrials